Company intelligence / Profile preview

CURTIL

Lexington, Massachusetts, United Statesdnb.com ↗

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Curis is a clinical-stage biotechnology company focused on developing first-in-class therapeutics for cancer. Its lead asset emavusertib targets IRAK4-driven hematologic malignancies such as AML/MDS and lymphomas. The company also has immune checkpoint inhibitors in its pipeline and outlicensed its approved drug Erivedge to Genentech/Roche for advanced basal cell carcinoma. Emavusertib has received Orphan Drug Designation in the US/EU for PCNSL, AML, MDS; pivotal studies are ongoing with regulatory engagement supporting potential accelerated approval pathways.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeImmune checkpoint inhibitorHedgehog pathway inhibitorHDAC/PI3K inhibitor
Industry: Biotech

Partnerships

Genentech/RocheAurigene Discovery TechnologiesNational Cancer Institute

Beyond the preview

Go deeper on CURTIL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CURTIL.

Explore the full profile